3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
80
Stomach Neoplasms
66
Rectal Neoplasms
39
Pancreatic Neoplasms
31
Colonic Neoplasms
27
Esophageal Neoplasms
24
Lymphoma, Large B-Cell, Diffuse
20
Neoplasms
19
Adenocarcinoma
19
Cholangiocarcinoma
16
Neoplasm Metastasis
15
Adenocarcinoma Of Esophagus
14
Biliary Tract Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Ovarian Neoplasms
10
Gastrointestinal Neoplasms
7
Gallbladder Neoplasms
7
Carcinoma, Hepatocellular
7
Locally Advanced Rectal Cancer
6
Esophageal Squamous Cell Carcinoma
6
Endometrial Neoplasms
6
Recurrence
4
Lymphoma
4
Carcinoma
4
Bile Duct Neoplasms
4
Advanced Solid Tumors
4
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Peritoneal Neoplasms
3
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dihydropyrimidine Dehydrogenase Deficiency
×
Oxaliplatin
×
1 year
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled